Diabetes Project Update (14 Aug 2009)Compound:
Phenyl propionic acid derivative No 3
Company Name:
Adamed Sp. z o.o. (Private)
Product Name:
Compound no 3
Indication:
Diabetes Type 2
Drug Class:
Diabetes (A10)
Trial Phase:
IND/Phase I
Route of Administration:
Oral
Mechanism of Action:
Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-Gamma) Partial Agonist
Mode of Action:
Hypoglycemic; Insulin Sensitizer
Milestones:
The company expects to initiate Phase I in January 2010.
Description:
Compound no 3 is an orally administered active small molecule drug candidate that is a partial agonist of PPAR gamma (peroxisome proliferator activated receptor gamma), a transcription factor involved in regulating of genes controlling carbohydrates and lipids metabolism, as well as insulin response to food intake. Compound no 3 is phenyl propionic acid derivative and is not structurally related to the thiazolidinedione (TZD) group of PPAR gamma agonists.